Brokerages Set Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) PT at $473.87

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) have earned an average recommendation of “Moderate Buy” from the twenty-six analysts that are presently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $473.8717.

Several brokerages have recently commented on ALNY. Barclays initiated coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 28th. They set an “overweight” rating and a $527.00 price target on the stock. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Thursday, January 15th. Canaccord Genuity Group upped their price objective on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Leerink Partners lowered their target price on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a research report on Monday, December 15th. Finally, Freedom Capital upgraded Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 17th.

Alnylam Pharmaceuticals Trading Down 3.0%

Shares of NASDAQ ALNY opened at $318.85 on Tuesday. The stock has a market cap of $42.29 billion, a price-to-earnings ratio of 186.46 and a beta of 0.39. The business has a 50 day simple moving average of $327.55 and a 200 day simple moving average of $396.63. Alnylam Pharmaceuticals has a 52 week low of $205.87 and a 52 week high of $495.55. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.18). The business had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. Alnylam Pharmaceuticals’s revenue was up 84.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.65) EPS. On average, research analysts predict that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Jeffrey V. Poulton sold 2,780 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $362.87, for a total value of $1,008,778.60. Following the transaction, the executive vice president directly owned 57,465 shares of the company’s stock, valued at approximately $20,852,324.55. This trade represents a 4.61% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the business’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $370.33, for a total value of $848,055.70. Following the completion of the sale, the executive vice president owned 21,264 shares of the company’s stock, valued at approximately $7,874,697.12. This trade represents a 9.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 53,923 shares of company stock worth $18,072,087. Insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of ALNY. Root Financial Partners LLC acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at $25,000. Salomon & Ludwin LLC acquired a new position in Alnylam Pharmaceuticals during the 3rd quarter worth $27,000. MV Capital Management Inc. bought a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at about $25,000. Caitong International Asset Management Co. Ltd bought a new stake in Alnylam Pharmaceuticals during the third quarter valued at about $29,000. Finally, HM Payson & Co. acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $27,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.